3 results
Primary Objectives: * to establish - which is the best treatment, MTX or baricitinib, to ensure rapid symptom relief of recent onset UA, based on clinical and patient reported outcomes from baseline to 3 months. Secondary Objective: * to establish…
To Evaluate the safety and efficacy of the sirolimus-eluting stent system BioMime Compared to the Abbott's XIENCE (V Xpedition or Prime) Everolimus-eluting stent system in the treatment of patients with up to two de novo native coronary artery…
This study is designed to assess the efficacy of pralsetinib as compared to Investigator*s choice platinum-based chemotherapy regimen for patients with metastatic NSCLC harboring an oncogenic RET fusion and who have not received prior systemic…